6533b851fe1ef96bd12a8d7e

RESEARCH PRODUCT

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL

Florinda Di PiazzaAntonio RussoAngelo Davide ContrinoSimona RasoMariano SardoMarco BonoPaolo CasimiroSalvatrice MancusoSergio SiragusaAlessandro PerezMarco SantoroVincenzo Accurso

subject

medicine.medical_specialtyEndotheliumGastroenterologySettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicinePolycythemia veraInternal medicineDiabetes mellitushemic and lymphatic diseasesmedicinePlateletEssential ThrombocythemiaPolycythemia VeraThrombotic riskEssential thrombocythemiabusiness.industrylcsh:RC633-647.5Hematologylcsh:Diseases of the blood and blood-forming organsmedicine.diseaseObesityPolycythemia vera Essential ThrombocytemiaInfectious Diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisOriginal ArticlebusinessDyslipidemia030215 immunology

description

Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to promoting the thrombotic event due to the interaction between platelets, leukocytes, and endothelium alterations. Moreover, a significant role can be played by cardiovascular risk factors (CV.R) such as cigarette smoking habits, hypertension, diabetes, obesity and dyslipidemia. In this study, we evaluated the impact that CV.R plays on thrombotic risk and survival in patients with PV and ET .

yearjournalcountryeditionlanguage
2019-09-08Mediterranean Journal of Hematology and Infectious Diseases
10.4084/mjhid.2020.008http://mjhid.org/index.php/mjhid/article/view/4061